A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...

Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...

The 2026 Priestley Medalist and Nobel laureate struggled with finding her way through school before achieving the greatest feats in science ...

CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...

Mitochondria possess their own mRNA translation system, mediated by specialized mitoribosomes. Dysregulation of mitochondrial translation disrupts metabolic homeostasis and is linked to various ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

The FDA is freeing Intellia Therapeutics' CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the ...

Shares for Intellia Therapeutics climbed by about 10% early Tuesday after the company said the Food and Drug Administration cleared it to resume one of two Phase 3 trials evaluating its experimental ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively cured through the use of CRISPR gene editing technology. But the rollout of ...